Werewolf Therapeutics Announces Asset Sale to EMD Serono for $33M

What Happened

• Werewolf Therapeutics, Inc. announced on August 14, 2026 that it closed an asset purchase agreement with EMD Serono Research & Development Institute Inc. The company sold pre-clinical assets from its INDUCER and portions of its INDUKINE platforms to EMD for $28.0 million upfront and an additional $5.0 million payable upon completion of the technology transfer.
• Werewolf retained all rights needed to continue clinical development of its two clinical-stage programs, WTX-124 and WTX-330, and simultaneously entered a License Agreement with EMD that grants Werewolf an exclusive license to certain patents needed to run those clinical programs.

Key Details

• Closing date: August 14, 2026.
• Consideration: $28.0M upfront + $5.0M contingent on transfer completion (total potential $33.0M).
• Assets sold: pre-clinical INDUCER platform (patents, know-how, pre-clinical compounds) and parts of the INDUKINE platform; clinical programs for WTX-124 and WTX-330 were excluded and retained by Werewolf.
• Contract terms: customary representations, warranties and indemnities; a 24‑month non‑competition covenant by Werewolf covering exploitation of certain compounds/products directed to the same tumor targets as Transferred Compounds, subject to standard exceptions.
• License back: EMD granted Werewolf an exclusive license to patents in the transferred assets to enable continued clinical development of WTX-124 and WTX-330 and to permit certain sublicensing to Harpoon Therapeutics and Jazz Pharmaceuticals consistent with prior agreements.

Why It Matters

• This transaction monetizes Werewolf’s pre-clinical assets, providing near-term cash of $28M (with $5M additional possible), while preserving the company’s control of its clinical-stage programs WTX-124 and WTX-330. For investors, the deal reduces non‑core pre-clinical exposure and supplies capital that can be used to advance the retained clinical programs. The license back and sublicensing permissions maintain Werewolf’s ability to keep clinical development on track and honor existing partner arrangements.